Literature DB >> 20467370

Pediatric aspects in Graves' orbitopathy.

Apostolos I Gogakos1, Kostas Boboridis, Gerasimos E Krassas.   

Abstract

Although pediatric Graves' disease is an uncommon condition, children have about the same (or slightly increased) risk as adults to develop Graves' ophthalmopathy (GO) once they have contracted Graves' hyperthyroidism. GO occurs in the same proportion between sexes but with a milder clinical presentation compared with adults. Lid lag, soft tissue involvement and proptosis are the commonest manifestations, whereas restricted eye muscle motility, severe strabismus and optic neuropathy are practically absent. Genetic, immunologic and environmental factors may be associated with the different appearance of GO in children and adolescents. Interestingly, manifestation of GO begins to resemble the adult findings more closely when adolescence approaches. This could be explained by increasing smoking prevalence with age as long as smoking is a proven to be a risk factor for GO, and the odds increase significantly with increasing severity of GO. Management of hyperthyroidism is essential for the control of complications and seems to offer improvement of eye changes upon restoration of euthyroidism. Antithyroid drugs are the first choice treatment. Lasting remission rates though are achieved in less than 30% of cases. Long periods of therapy are needed and risk for side effects (often serious) increases. In resistant or severe cases early radical treatment with surgery or radioiodine is needed. Both can be equally effective and safe in selected cases. Identification of subjects prone to relapses is critical for optimal management. Regarding treatment of thyroid eye disease in childhood, most physicians who are dealing with such cases prefer a 'wait-and-see' policy. Pharmacological intervention, predominantly with steroids, is considered appropriate in case of deterioration or no improvement of eye changes when the patient has become euthyroid. It has been shown that somatostatin analogs (SM-as) might be of therapeutic value in the treatment of active eye disease in adults. Newer generations of SM-as that target a wider range of somatostatin receptors may show markedly superior results in the treatment of ophthalmopathy. Surgical orbital decompression is hardly ever necessary due to the mild nature of the disease, while retrobulbar irradiation, which has been proved beneficial in adults, has no place in the treatment of juvenile GO, in view of the theoretical risk of tumor induction.

Entities:  

Mesh:

Year:  2010        PMID: 20467370

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  4 in total

1.  Association between age at diagnosis of Graves' disease and variants in genes involved in immune response.

Authors:  Beata Jurecka-Lubieniecka; Rafal Ploski; Dorota Kula; Aleksandra Krol; Tomasz Bednarczuk; Zofia Kolosza; Andrzej Tukiendorf; Sylwia Szpak-Ulczok; Anita Stanjek-Cichoracka; Joanna Polanska; Barbara Jarzab
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

2.  Predictive Factors of Development of Graves' Ophthalmopathy for Patients with Juvenile Graves' Disease.

Authors:  Dalia Jarusaitiene; Rasa Verkauskiene; Vytautas Jasinskas; Jurate Jankauskiene
Journal:  Int J Endocrinol       Date:  2016-06-16       Impact factor: 3.257

3.  Guidelines for the treatment of childhood-onset Graves' disease in Japan, 2016.

Authors:  Kanshi Minamitani; Hirokazu Sato; Hidemi Ohye; Shohei Harada; Osamu Arisaka
Journal:  Clin Pediatr Endocrinol       Date:  2017-04-22

4.  Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?

Authors:  Laura Penta; Giulia Muzi; Marta Cofini; Alberto Leonardi; Lucia Lanciotti; Susanna Esposito
Journal:  Int J Environ Res Public Health       Date:  2019-01-08       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.